Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will give Agenus full control of assets that it will consider advancing ...

Citi lowered the firm’s price target on Incyte (INCY) to $88 from $97 and keeps a Buy rating on the shares. The company reported Q4 results, ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...